Evidence map›Paper›PMID 34680167›Full record

ArticleBiomolecules2021

CRMP2 as a Candidate Target to Interfere with Lung Cancer Cell Migration.

Xabier Morales, Rafael Peláez, Saray Garasa, Carlos Ortiz de Solórzano, Ana Rouzaut

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Drug Repurposing for Cancer Treatment: A Comprehensive Review.International journal of molecular sciences · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xabier MoralesSolid Tumors and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Avda Pío XII, 55, 31008 Pamplona, Spain.
Rafael PeláezCenter for Biomedical Research of La Rioja (CIBIR), Neurodegeneration Area, Biomarkers and Molecular Signaling Group, Piqueras 98, 26006 Logroño, Spain.ORCID 0000-0002-4047-6017
Saray GarasaInstituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain.ORCID 0000-0001-5192-2599
Carlos Ortiz de SolórzanoSolid Tumors and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Avda Pío XII, 55, 31008 Pamplona, Spain.ORCID 0000-0001-8720-0205
Ana RouzautInstituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain.ORCID 0000-0003-3226-9162
Navarre Institute of Health Research · ESCenter for Biomedical Research of La Rioja · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Collapsin response mediator protein 2 (CRMP2) is an adaptor protein that adds tubulin dimers to the growing tip of a microtubule. First described in neurons, it is now considered a ubiquitous protein that intervenes in processes such as cytoskeletal remodeling, synaptic connection and trafficking of voltage channels. Mounting evidence supports that CRMP2 plays an essential role in neuropathology and, more recently, in cancer. We have previously described a positive correlation between nuclear phosphorylation of CRMP2 and poor prognosis in lung adenocarcinoma patients. In this work, we studied whether this cytoskeleton molding protein is involved in cancer cell migration. To this aim, we evaluated CRMP2 phosphorylation and localization in the extending lamella of lung adenocarcinoma migrating cells using in vitro assays and in vivo confocal microscopy. We demonstrated that constitutive phosphorylation of CRMP2 impaired lamella formation, cell adhesion and oriented migration. In search of a mechanistic explanation of this phenomenon, we discovered that CRMP2 Ser522 phospho-mimetic mutants display unstable tubulin polymers, unable to bind EB1 plus-Tip protein and the cortical actin adaptor IQGAP1. In addition, integrin recycling is defective and invasive structures are less evident in these mutants. Significantly, mouse xenograft tumors of NSCLC expressing CRMP2 phosphorylation mimetic mutants grew significantly less than wild-type tumors. Given the recent development of small molecule inhibitors of CRMP2 phosphorylation to treat neurodegenerative diseases, our results open the door for their use in cancer treatment.

Indexed as

Adenocarcinoma of LungAnimalsCell MovementCell ProliferationCytoskeletonGene Expression Regulation, NeoplasticHeterograftsHumansIntercellular Signaling Peptides and ProteinsMiceMicrotubule-Associated ProteinsMicrotubulesNerve Tissue ProteinsPhosphorylationras GTPase-Activating ProteinsTubulincollapsin response mediator protein-2Intercellular Signaling Peptides and ProteinsIQ motif containing GTPase activating protein 1MAPRE1 protein, humanMicrotubule-Associated ProteinsNerve Tissue Proteinsras GTPase-Activating ProteinsTubulinCRMP2cytoskeletonlung cancermigration

Identifiers

PMID34680167
PMCPMC8533992
OpenAlexW3205661775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.